Reglan and Tardive Dyskinesia: Key Questions for Illinois Clinicians

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure Concerns

If you are a clinician in Illinois prescribing Reglan (metoclopramide), you may be concerned about the risk of tardive dyskinesia. Decades of pharmacovigilance have established this movement disorder as a known adverse effect of long-term metoclopramide use. This page addresses key questions about risk factors, symptom recognition, and monitoring strategies for Illinois practitioners.

Reglan and Tardive Dyskinesia: Clinical and Pharmacological Overview

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux and diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This section examines the clinical presentation of TD, the pharmacology of Reglan, the mechanistic link between the drug and TD, and key considerations for affected patients in Illinois, including statute of limitations and settlement-related factors. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. According to the FDA-approved labeling for Reglan, TD is 'a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can also suppress or partially suppress its own signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis is typically clinical, based on patient history and observation of characteristic movements, and may be confirmed by a neurologist. Early detection is critical because TD can become permanent if the drug is not discontinued promptly.

Mechanistic Pathways and Warning Adequacy

The mechanism by which Reglan causes TD is related to its dopamine-blocking properties. Chronic blockade of dopamine D2 receptors in the basal ganglia can lead to upregulation of these receptors and subsequent supersensitivity, which is thought to underlie the involuntary movements of TD. The FDA boxed warning states that 'the risk of developing TD increases with duration of treatment and total cumulative dosage' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This dose- and duration-dependent risk underscores the importance of using Reglan for the shortest possible time. The FDA has required a boxed warning for Reglan since 2009, which is the strongest warning level. The warning states: 'Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also notes that Reglan is contraindicated in patients with a history of TD and that treatment should be for the shortest duration, with periodic reassessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, before the boxed warning was added. The adequacy of warnings prior to 2009 has been a subject of litigation, with plaintiffs arguing that earlier labeling did not sufficiently communicate the risk of TD.

Statute of Limitations and Settlement Considerations in Illinois

Patients who developed TD after using Reglan may be eligible for compensation through settlements or lawsuits. Key considerations include the statute of limitations, which varies by state. In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For TD, this can be complex because symptoms may develop gradually. The timeline between exposure and documented harm is critical: TD can appear months or years after starting Reglan, and even after the drug is discontinued. The FDA warns that 'metoclopramide, including Reglan, may also suppress, or partially suppress, the signs of TD, and may delay the diagnosis of TD' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can make it difficult for patients to recognize the connection between their symptoms and the medication. The risk of TD increases with longer exposure. The labeling advises that for patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks, and if longer use is unavoidable, patients should be routinely monitored for TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were prescribed Reglan for months or years, leading to cumulative exposure that significantly raises TD risk. Once TD develops, it may be irreversible, and the patient may require lifelong management. The FDA recommends immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For Illinois residents, the statute of limitations for filing a claim is typically two years from discovery of the injury. Patients who developed TD after Reglan use should consult with a legal professional to understand their rights and potential settlement options. Early legal advice is crucial due to the time-sensitive nature of such claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered. Because TD symptoms can develop gradually and may be masked by the drug, the discovery date can be complex. It is important to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

Can I still file a claim if my Reglan use was years ago?

It depends on when you discovered or reasonably should have discovered that your tardive dyskinesia was caused by Reglan. The two-year statute of limitations in Illinois begins at the time of discovery. If you only recently learned of the connection, you may still have time to file. However, delays can jeopardize your claim, so seeking legal advice as soon as possible is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Reglan

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.